Catheter Precision Completes Patient Follow-up For The VIVO European Registry And New Product Evaluations Of VIVO
Portfolio Pulse from Benzinga Newsdesk
Catheter Precision, Inc. (NYSE:VTAK) has completed the patient follow-up phase for the VIVO European Registry, which began in October 2021 and concluded patient enrollment in June 2023. The data collected will fulfill European regulatory requirements and aid in future studies and improvements to the VIVO technology. The data is expected to be available in Q4 2024.
July 16, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catheter Precision has completed the patient follow-up phase for the VIVO European Registry, which will provide important data for regulatory requirements and future product improvements. The data is expected to be available in Q4 2024.
The completion of the patient follow-up phase for the VIVO European Registry is a significant milestone for Catheter Precision. The data collected will help fulfill regulatory requirements and support future product improvements, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100